Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma

doi:10.4251/wjgo.v17.i4.103776

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (913)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

HTML

548

Figures (1-5)

106

Tables (1-4)

108

Sum=830

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=42

Apr 15, 2025 (publication date) through May 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103776
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103776

Full Size Figure Download Figure

Figure 5 Kaplan-Meier curves. A: Overall survival; B: Progression-free survival. IDA: Idarubicin; GemCis: Gemcitabine and cisplatin; TACE: Transarterial chemoembolization; OS: Overall survival; PFS: Progression-free survival.

Citation: Zhao CH, Liu H, Pan T, Xiang ZW, Mu LW, Luo JY, Zhou CR, Li MA, Liu MM, Yan HZ, Huang MS. Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma. World J Gastrointest Oncol 2025; 17(4): 103776
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103776.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103776